There is one clinical trial.
This clinical trial will evaluate the safety, tolerability and effectiveness of topical
GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.
Primary Outcomes
Measure: Evaluate the number of GLS-1200 topical nasal spray adverse events as assessed by CTCAE v5.0 Time: 4 weeks of treatment
Measure: Incidence of SARS-CoV-2 infection, confirmed by PCR relative to treatment group Time: 4 weeks of treatment
Secondary Outcomes
Measure: Symptom score of documented SARS-CoV-2 infection relative to treatment group with a higher score being a worse outcome. Time: 4 weeks of treatment